Matthew Schissler, through his leadership at Cord Blood America, Inc. (CBAI), shifted the private sector’s approach to neonatal stem cell banking. By commodifying the storage of umbilical cord blood, his ventures influenced how families perceive long-term biological insurance, despite ongoing medical debates regarding the clinical utility of private versus public banking.
In Plain English: The Clinical Takeaway
- Biological Insurance: Cord blood contains hematopoietic stem cells (HSCs), which can be used to treat specific blood disorders like leukemia or lymphoma.
- Private vs. Public: Private banking reserves cells exclusively for the donor family, while public banks make them available for any matched patient in need.
- Clinical Utility: Most medical associations, including the American Academy of Pediatrics, currently discourage routine private banking for families without a known risk factor for genetic disease.
The Biological Mechanism of Cord Blood Banking
The core proposition of Cord Blood America, Inc. centers on the cryopreservation of umbilical cord blood. Following birth, the blood remaining in the placenta and umbilical cord is rich in hematopoietic stem cells (HSCs). These multipotent cells have the capacity to differentiate into various blood cell types, including red blood cells, white blood cells, and platelets. The mechanism of action for therapeutic use involves the transplantation of these cells into a patient whose own bone marrow has been compromised by disease or chemotherapy.
However, the clinical necessity of private storage remains a point of contention. According to the National Institutes of Health (NIH), the probability that a child will require their own stored cord blood for a transplant is extremely low, estimated between 1 in 1,000 and 1 in 200,000. Most transplants performed today utilize cells from public banks, where the genetic diversity of donors increases the likelihood of finding a suitable human leukocyte antigen (HLA) match for patients in need.
Regulatory Oversight and Public Health Standards
In the United States, the Food and Drug Administration (FDA) regulates cord blood as both a “drug” and a “biologic product.” Companies like CBAI must operate under stringent Current Good Tissue Practice (cGTP) regulations to ensure the safety and viability of stored units. These regulations mandate rigorous screening for infectious diseases and standardized protocols for collection and processing to prevent contamination.
While Schissler’s business model focused on the accessibility of these services, the public health community emphasizes the importance of informed consent. Parents are often targeted by marketing that frames private banking as a “miracle” safeguard. Dr. Joanne Kurtzberg, a pioneer in cord blood transplantation at Duke University, has frequently noted that while the science of stem cell therapy is robust, the marketing of private banking often outpaces the clinical evidence for its necessity in healthy families.
| Banking Type | Primary Use Case | Accessibility | Clinical Recommendation |
|---|---|---|---|
| Public Bank | Allogenic (donor-to-recipient) | Global registries (e.g., NMDP) | Recommended for general population |
| Private Bank | Autologous (self-use) | Family-exclusive | Recommended only for high-risk families |
Funding Transparency and Industry Ethics
The growth of the cord blood banking industry has been fueled by private equity and public market investment, rather than foundational clinical research grants. Unlike Phase III clinical trials, which are typically funded by the National Institute of Allergy and Infectious Diseases (NIAID) or pharmaceutical entities, the business of cord blood storage relies on a direct-to-consumer revenue model. This creates a fundamental misalignment: medical research is driven by patient outcomes, while the private banking industry is driven by long-term storage fees and contract renewals.
As noted in a report by the American College of Obstetricians and Gynecologists (ACOG), the medical community maintains that there is no scientific evidence to support the banking of cord blood for “future potential” therapies that remain experimental, such as regenerative medicine for neurological conditions.
Contraindications & When to Consult a Doctor
There are no medical “contraindications” to the act of banking cord blood itself, as the collection process is non-invasive and poses no risk to the infant. However, the decision to invest in private banking should be subject to a clinical risk assessment. If your family has a history of hematological malignancies or genetic disorders, you should consult with a genetic counselor or a pediatric hematologist.
If you are being pressured by marketing materials to store cord blood, consult your obstetrician to discuss the actual statistical probability of needing those cells. Symptoms such as unexplained bruising, pallor, or persistent fatigue in a child should always be evaluated by a pediatrician, regardless of whether cord blood was banked at birth.
Future Trajectory of Regenerative Medicine
The narrative surrounding Matthew Schissler and CBAI represents a broader era in biotechnology where the intersection of finance and medicine became increasingly blurred. While the technology for cryopreservation is scientifically sound and life-saving in specific clinical contexts, the value proposition to the average consumer remains skewed. As we advance toward 2027, the focus of medical science is shifting away from simple storage and toward the expansion of stem cells in the laboratory—a development that may eventually render the need for private, family-exclusive storage obsolete.
